Essentials for Clinicians: Neuro-Oncology - Editors and Contributors

Editors

  • Matthias Preusser, Department of Medicine I, Comprehensive Cancer Center Vienna, Vienna, Austria
  • Michael Weller, Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland

Series editor: Michele Ghielmini, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

Contributors

Chapter 1 - Epidemiology, Pathogenesis and Risk Factors of Brain Tumours

  • L Bauchet - Department of Neurosurgery and French Brain Tumor DataBase, Hôpital Gui de Chauliac, Montpellier, France
  • V Rigau - Department of Pathology and French Brain Tumor DataBase, Hôpital Gui de Chauliac, Montpellier, France

Chapter 2 - Clinical Presentation, Differential Diagnosis and Response Assessment of Gliomas

  • R Henriksson - Regional Cancer Centre Stockholm Gotland; Department of Radiation Sciences, Umeå University Hospital, Umeå, Sweden
  • M Bergqvist - Department of Oncology, Gävle Hospital, Gävle, Sweden; Department of Radiation Sciences & Oncology, Umeå University Hospital, Umeå, Sweden

Chapter 3 - Histology and Molecular Pathology of Gliomas

  • P Wesseling - Department of Pathology, VU University Medical Center/Brain Tumor Center, Amsterdam, Netherlands; Diagnostic Laboratory, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pathology, University Medical Center Utrecht, Netherlands

Chapter 4 - Treatment Strategies for Anaplastic Astrocytoma and Glioblastoma

  • M Weller - Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
  • M Hegi - Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery, Department of Clinical Neurosciences, University Hospital Lausanne, Lausanne, Switzerland

Chapter 5 - Treatment Strategies for Low-grade Gliomas

  • BG Baumert - Department of Radiation-Oncology, MediClin Robert-Janker-Clinic; Clinical Cooperation Unit Neurooncology, University of Bonn Medical Centre, Bonn, Germany and Department of Radiation-Oncology, Paracelsus Clinic Osnabrueck, Germany
  • AF Hottinger - Departments of Clinical Neurosciences & Oncology, CHUV Lausanne University Hospital, Lausanne University, Lausanne, Switzerland

Chapter 6 - The Essentials in Radiation Oncology for Brain Tumours

  • M Brada - Academic Unit of Radiation, Oncology Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
  • T Ajithkumar - Department of Clinical Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Chapter 7 - Surgery, Indications and Limitations

  • O Schnell - Department of Neurosurgery, Klinikum der Ludwig-Maximilians-Universität München Campus Grosshadern, Munich, Germany; Department of Neurosurgery, Medical Center - University of Freiburg, Freiburg, Germany
  • J-C Tonn - Department of Neurosurgery, Klinikum der Ludwig-Maximilians-Universität München Campus Grosshadern, Munich, Germany

Chapter 8 - Management of CNS Metastases

  • M Preusser - Department of Medicine I, Comprehensive Cancer Center Vienna, Vienna, Austria

 Chapter 9 - Treatment of Oligodendroglioma (IDHmt, 1p/19q Codeleted)

  • F Ducray - Neuro-Oncology, Hôpital Neurologique de Lyon, Lyon, France
  • MJ van den Bent - Department of Neuro-Oncology/Neurology, Erasmus MC Cancer Center, Rotterdam, Netherlands

Chapter 10 - Classification and Treatment Strategies of Meningiomas

  • C Mawrin - Department of Neuropathology, Otto-von-Guericke-University, Magdeburg, Germany
  • M Preusser - Department of Medicine I, Comprehensive Cancer Center Vienna, Vienna, Austria

Chapter 11 - Classification and Treatment of Paediatric Brain Tumours

  • R Riccardi - Università Cattolica del Sacro Cuore, Rome, Italy
  • D Rizzo - Università Cattolica del Sacro Cuore, Rome, Italy
  • F Giangaspero - Department of Radiological, Oncological and Anatomopathological Sciences, University Sapienza of Rome, Rome, Italy; IRCCS Neuromed, Pozzilli, Italy

Chapter 12 - Anticoagulation and Management of Seizures and Brain Oedema in Brain Tumour Patients

  • C Marosi - Medical University of Vienna, Clinical Division of Medical Oncology, Department for Internal Medicine I, Vienna, Austria
  • S Oberndorfer - Department for Neurology, University Clinic St. Pölten, KLPU, KLI-Clinical Neurology and Neuropsychology, St. Pölten, Austria

Chapter 13 - Management of Spinal Tumours

  • S-O Eicker - Department of Neurosurgery, University Medical Center, Hamburg-Eppendorf, Germany
  • M Westphal - Department of Neurosurgery, University Medical Center, Hamburg-Eppendorf, Germany

Declarations of interest

  • T Ajithkumar: No conflicts of interest.
  • L Bauchet: No conflicts of interest.
  • BG Baumert: Travel support from MSD, Roche, Noxxon; compensation for advisory board participation from Noxxon.
  • M Bergqvist: Advisory board for Lilly Pharma, MSD, Bristol-Myers-Squibb.
  • M Brada: No conflicts of interest.
  • F Ducray: Research support from Roche, GlaxoSmithKline, Bristol-Myers-Squibb, UCB, Novocure.
  • S-O Eicker: Scientific advisor for Stryker, Spineart.
  • F Giangaspero: No conflicts of interest.
  • M Hegi: Compensation for lectures or advisory board participation from MSD, Roche/Genentech, MDxHealth, Novocure.
  • R Henriksson: No conflicts of interest.
  • AF Hottinger: Travel support from Roche, MSD, Novocure.
  • C Marosi: No conflicts of interest.
  • C Mawrin: No conflicts of interest.
  • S Oberndorfer: No conflicts of interest.
  • M Preusser:Research support from Böhringer- Ingelheim, GlaxoSmithKline, Merck Sharp & Dome, Roche; honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, AstraZeneca.
  • R Riccardi: No conflicts of interest.
  • V Rigau: No conflicts of interest.
  • D Rizzo: No conflicts of interest.
  • O Schnell: Honoraria for advisory board participation or consulting from Novocure, Roche.
  • J-C Tonn: No conflicts of interest.
  • MJ van den Bent: Research support from Roche, Abbvie; honoraria from Roche, Abbvie, Novocure, Actelion, Merck Ag, Cavion.
  • M Weller: Research grants from Acceleron, Actelion, Alpinia Institute, Bayer, Isarna, MSD, Merck & Co, Novocure, PIQUR, Roche; honoraria for lectures or advisory board participation or consulting from Celldex, Immunocellular Therapeutics, Isarna, Magforce, MSD, Merck & Co, Northwest Biotherapeutics, Novocure, Pfizer, Roche, Teva.
  • P Wesseling: No conflicts of interest.
  • M Westphal: No conflicts of interest.
<\p>

« Previous Page Next Page »

Last update: 18 September 2017